Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:07:27.685Z.
Calculation as of: 2026-10-06T15:07:27.685Z.
Quote observation: 2026-10-06T15:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f4beac4ac45f8a46ab4983c5a571fa9813be082d6d81805b5cbd768b9d0a60c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$5.68M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.98M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.80M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.84M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.57M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.17M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.27M | N/A | 1.29% | 1.35% | 1.32% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
